DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT) announced it filed its 2025 Annual Report on Form 10-K with the SEC and its 2025 Universal Registration Document (2025 URD) with the AMF on March 26, 2026.
The 2025 URD includes the annual financial report, the Board of Directors' corporate governance report under Article L.225-37, the description of the share buy-back program, statutory auditor reports, and auditor fees. Documents are available on the company website, the SEC site, and the AMF site.
Positive
- None.
Negative
- None.
Market Reality Check
Peers on Argus
Momentum data flagged only 1 peer (ANNX) moving in the same direction, with overall biotech peers showing mixed single-day changes, suggesting company-specific dynamics rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Index inclusion | Positive | +3.7% | Inclusion in CAC Mid 60 and SBF 120 indices following Euronext review. |
| Mar 04 | Investor conferences | Neutral | -3.1% | Participation in March 2026 investor events and webcasted fireside chat. |
| Mar 03 | Capital structure update | Neutral | +4.2% | Disclosure of total shares and voting rights as of February 28, 2026. |
| Feb 10 | Clinical data update | Positive | -5.0% | Additional data from positive VITESSE Phase 3 VIASKIN Peanut study. |
| Feb 09 | Investor summit | Neutral | +7.1% | CEO fireside chat at Guggenheim Emerging Outlook: Biotech Summit. |
Recent news has often triggered sizeable single-day moves, with both positive and neutral items sometimes followed by sharp gains or declines, indicating event-sensitive trading.
Over the past few months, DBV Technologies has reported index inclusion in the CAC Mid 60 and SBF 120, multiple investor conference appearances, and updates on voting rights and share count as of February 28, 2026. It also highlighted additional data from the VITESSE Phase 3 study of the VIASKIN Peanut Patch. Price reactions to these items have been mixed, with moves ranging from about -5% to over +7%, underscoring that even routine or neutral disclosures can coincide with notable volatility.
Market Pulse Summary
This announcement centers on DBV Technologies’ filing of its 2025 Annual Report on Form 10-K with the SEC and its 2025 Universal Registration Document with the AMF, providing audited financials, governance reporting, and share buy-back program details. Historically, the stock has shown pronounced moves around both neutral corporate updates and major clinical milestones, such as the VITESSE Phase 3 data. Investors may focus on the newly filed documents for insights into strategy, governance, and any updated risk disclosures.
Key Terms
form 10-k regulatory
universal registration document regulatory
AI-generated analysis. Not financial advice.
Châtillon, France, March 26, 2026
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”).
In compliance with French law, the following information are included in the 2025 URD :
- The 2025 annual financial report;
- The Board of Directors’ corporate governance report (“rapport sur le gouvernement d’entreprise”) required under Article L. 225-37 of the French Commercial Code;
- The description of the share buy-back program;
- The statutory auditor reports;
- The information regarding the statutory auditor fees.
These documents can be accessed on the Regulated Information section of the Company's website at www.dbv-technologies.com. In addition, the Form 10-K is available on the SEC’s website at www.sec.gov and the 2025 URD on the AMF’s website at www.amf-france.org.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children.
Through epicutaneous immunotherapy (EPIT), the VIASKIN® Patch is designed to
introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks
to modify an individual’s underlying allergy by re-educating the immune system to
become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic
people. The Company’s food allergy programs include ongoing clinical trials of the
VIASKIN® Peanut Patch in peanut allergic toddlers (1 through 3 years of age) and
children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American
operations in Warren, NJ. The Company’s ordinary shares are traded on segment B
of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbvtechnologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Investor Contact
Jonathan Neely
DBV Technologies
Jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
Brett.whelan@dbv-technologies.com
Attachment
FAQ
Did DBV Technologies (DBVT) file its 2025 Form 10-K and 2025 URD on March 26, 2026?
Where can investors access DBV Technologies' 2025 Form 10-K and 2025 URD for DBVT?
Does the 2025 URD for DBVT include information about a share buy-back program?
What corporate governance disclosures are included in DBV Technologies' 2025 URD (DBVT)?
Does DBV Technologies' 2025 URD provide statutory auditor reports and fee information for DBVT?
